A bill to amend the Pharmaceutical and Medical Devices (PMD) Law is expected to be submitted to the ordinary session of the Diet this year, which was convened on January 17 for a 150-day run. The proposed amendment is for…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Takeda Faces Generic Entry for Candesartan in US
December 18, 2012
-
BUSINESS Pfizer Specialty Care Chief Hopeful about Japan Vaccine Market, Novel RA Treatment
December 17, 2012
-
BUSINESS Elmed Eisai, Kobayashi Kako Get Their Allegra Generics Listed
December 14, 2012
-
BUSINESS Zydus to Build New Plant in India for Japan-Bound Generics
December 13, 2012
-
REGULATORY Strategy Council Proposes Revamped Framework to Oversee Entire Life Innovation Budgets
December 12, 2012
-
BUSINESS Mochida Revving Up Collaboration Efforts in Biosimilars
December 11, 2012
-
REGULATORY Long-Listed Products Not Granted Premium Should Be Exempted from New Rule: FPMAJ’s Kamoya
December 10, 2012
-
BUSINESS Actavis Eyes 3 Monoclonal Antibodies for Entry into Japanese Biosimilar Market: EVP
December 10, 2012
-
BUSINESS With Spiriva Combination Product in PIII, BI Not Fear Competition in COPD Market: Chairman Barner
December 7, 2012
-
REGULATORY CSIMC Subcommittee Agrees on Introduction of New Price-Cut Rule for Long-Listed Products
December 6, 2012
-
ORGANIZATION Drug Costs Should Be Basically Borne by Patients under Compassionate Use System: JPMA’s Kuwahara
December 5, 2012
-
ORGANIZATION 80 Medical Institutions Submit Comprehensive Agreements on Info Disclosure in Response to JPMA Transparency GLs
December 4, 2012
-
REGULATORY MHLW to Conduct Field Study for Japanese Version of “Compassionate Use” System
December 3, 2012
-
BUSINESS Fast-growing Plavix Could Become Japan’s No. 1 Ethical Drug by Next Year
December 3, 2012
-
BUSINESS CMIC MPSS to Offer Comprehensive Region-Wide CSO Service for Long-Listed Drugs
November 30, 2012
-
REGULATORY FPMAJ Chairman Naito Nudges CSIMC to Discuss Perpetuation of Premiums, Abolishment of Special Price Cuts for Long-Listed Drugs
November 29, 2012
-
ORGANIZATION IGPA Annual Conference to Adopt Kyoto Declaration including Int’l Harmonization on Generic Evaluation Criteria
November 28, 2012
-
BUSINESS Bayer Eyes Sales of €3 Billion in Japan by 2017: Chairman Dekkers
November 27, 2012
-
BUSINESS Health Professionals Voice Concerns over JPMA Transparency Guidelines
November 26, 2012
-
BUSINESS Decline in Sales of Long-listed Drugs Continues with a Double-punch from Generics, NHI Price Reductions
November 26, 2012
ページ
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…
Japan’s all-important reimbursement policy panel on December 22 approved an outline of the next drug pricing reform scheduled for April 2022, which embraces plans to reward innovative new indications and introduce a grace period for so-called “spillover” re-pricing.The reform outline…
Remember what it was like back in March, when we all started working from home? There was a distinct change in the air - a sense of freedom and excitement about the novelty of being able to work from home.…
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…